IN8BIO INC. - COMMON STOCK

0,2750

24-января-25 16:45:00

15 мин. задержка

Акции

-0,0118

-4,11%

Сегодняшний диапазон

0,2720 - 0,2850

ISIN

N/A

Источник

NASDAQ

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

30 апр 2024 06:05:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

24 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

16 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

09 апр 2024 16:30:00 Источник Nasdaq GlobeNewswire
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

14 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

05 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

14 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

04 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

11 дек 2023 16:05:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

11 дек 2023 09:00:47 Источник Nasdaq GlobeNewswire
IN8bio Appoints Dr. Corinne Epperly to Board of Directors

07 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

05 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

20 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

10 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 ноя 2023 16:00:00 Источник Nasdaq GlobeNewswire
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

06 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

03 ноя 2023 12:00:00 Источник Nasdaq GlobeNewswire
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

02 ноя 2023 09:17:21 Источник Nasdaq GlobeNewswire
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

01 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

12 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.